This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


ProNAi Therapeutics, Inc.

Drug Names(s): PNT141, PNT-141, AS-141, AS141

Description: AS-141 is a small molecule kinase inhibitor targeting CDC7.

CDC7 (cell division cycle 7) is a serine-threonine kinase positioned as an essential regulator of both DNA replication and DNA damage response, two critical functions required for tumor cell survival. Overexpression and activity of CDC7 is correlated with poor clinical outcomes and poor survival in a broad range of hematological malignancies and solid tumors. CDC7 inhibitors have been shown to trigger apoptosis (cancer cell death) in a p53-independent manner and to induce tumor stasis or regression in a variety of in vivo animal models.

Deal Structure: ProNAi and Carna
In May 2016, ProNAi Therapeutics announced it has obtained an exclusive license from Carna Biosciences for worldwide rights to develop and commercialize AS-141, a small molecule kinase inhibitor targeting CDC7. Under the terms of the agreement, ProNAi will pay Carna Biosciences an initial upfront payment of $0.9 million and aggregate additional potential payments upon achievement of certain developmental, regulatory and commercial milestones of up to $270 million. ProNAi will also pay Carna single-digit tiered royalties on the net sales of any product successfully developed.

Partners: Carna Biosciences, Inc.

PNT141 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug